Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More Recalls Seen For Ranitidine

Executive Summary

Sandoz is voluntarily recalling all ranitidine hydrochloride capsules in the US because of “confirmed’ NDMA contamination, while Dr Reddy’s is suspending global shipments of the generic version of Zantac due to worries about the presence of the suspected cancer-causing agent in its products, as suppliers around the world grapple with the issue.

You may also be interested in...



GSK Sells Indian Site To Hetero Labs

GSK has sold its Vemgal manufacturing plant to Indian company Hetero Labs. GSK’s decision came after the recall of ranitidine products made in India.

Ranitidine Recall Dents GSK India, Which Mulls Plant Sale

GlaxoSmithKline India’s Vemgal plant, which entailed a large investment outlay, may be put on the block as part of a review of assets impacted by the recall of ranitidine over NDMA impurity concerns. The site, which has “all relevant approvals”, has not made commercial supplies yet.

New Strides CEO Puts Emphasis On Execution

Strides' newly-appointed CEO, R Ananthanarayanan, sees no reason to change course as the firm's current strategy continues to yield positive results. The company posted a 29% increase in third-quarter revenues on the back of 62% growth in the US.

Related Content

Topics

UsernamePublicRestriction

Register

GB149207

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel